BriaCell Therapeutics Corp. (BCTX)

Market Cap	21.75M
Revenue (ttm)	n/a
Net Income (ttm)	-4.79M
Shares Out	35.84M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	621,585
Open	0.569
Previous Close	0.572
Day's Range	0.565 - 0.616
52-Week Range	0.460 - 5.970
Beta	1.82
Analysts	Strong Buy
Price Target	15.00 (+2,390.45%)
Earnings Date	Dec 12, 2024

About BCTX

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCTX
• Website: https://briacell.com

Analyst Forecast

According to one analyst, the rating for BCTX stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target

$15.0

(2,390.45% upside)

Analyst Consensus: Strong Buy